Compare ADMA Biologics Inc (ADMA) vs Marvell Technology Inc (MRVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Marvell Technology Inc — how do they compare? ADMA Biologics Inc trades at $9.96 (market cap $2.22B), while Marvell Technology Inc trades at $223.09 (market cap $190.56B). The key difference: Marvell Technology Inc is far larger — about 85.8× ADMA Biologics Inc's market cap, and Marvell Technology Inc pays a 0.11% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | MRVL | |
|---|---|---|
Market Cap | $2.22B | $190.56B |
Sector | Health | Technology |
52-Week High | $20.38 | $316.43 |
52-Week Low | $7.60 | $62.31 |
Enterprise Value | $2.29B | $191.99B |
Dividend Yield | — | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
Marvell Technology (MRVL) trades at $208.56, down 4.65% on the day, amid a broader semiconductor sell-off. The stock shows a bullish technical signal with support near $201 and resistance at $223. Fundamentally, while recent quarters have seen EPS beats, the company reported a net loss of $885 million for 2025, though revenue grew to $5.77 billion. Analyst sentiment remains strongly positive with an 82% buy rating and a $275.68 consensus price target, citing AI infrastructure growth drivers.
The outlook for MRVL is supported by its positioning in AI data center and optical networking markets, with partnerships like NVIDIA and Microsoft's Maia 300 offering significant upside. Key risks include intense competition, margin pressures, and geopolitical supply chain disruptions. Investors should weigh the high valuation multiples against the potential for AI-driven revenue acceleration in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →
